2025-09-12
Why campaign review boards stall after the third approval
By Narisa Wichitsongkhram
Review boards rarely fail because someone enjoys saying no. They stall when packets omit channel-level consent references or when clinical reviewers cannot see how a metric will be reported. We coach teams to attach a one-page evidence index before slides load so every discipline scans the same facts.
Dissent notes should describe what additional evidence resolves the pause, not restate generic risk. Boards that adopt this pattern in Bangkok and Kuala Lumpur cohorts reclaimed roughly two review cycles per quarter without lowering standards.
If your board still feels heavy, audit whether marketing and clinical leads rotate chair duties. Shared ownership keeps tone balanced and prevents any single function from becoming the perceived bottleneck.
Tags: Governance, Hospitals